SCHEMBL15480429

SCHEMBL15480429

Cc1ccc(NC(=O)CCCCCCC(=O)Nc2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 9/20 0.68
HDAC3 O15379 8/20 0.68
HDAC2 Q92769 8/20 0.68
HDAC6 Q9UBN7 7/20 0.68
HDAC10 Q969S8 6/20 0.68
HDAC8 Q9BY41 6/20 0.68
HDAC11 Q96DB2 5/20 0.68
NCOR2 Q9Y618 2/20 0.68
HDAC4 P56524 3/20 0.65
HDAC7 Q8WUI4 3/20 0.65
HDAC9 Q9UKV0 3/20 0.65
HDAC5 Q9UQL6 3/20 0.65
ALDH1A1 P00352 2/20 0.56
LMNA P02545 1/20 0.56
POLB P06746 3/20 0.55
MEN1 O00255 1/20 0.54
HTT P42858 1/20 0.54
KMT2A Q03164 1/20 0.54
NPSR1 Q6W5P4 1/20 0.54
EPHX2 P34913 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23054850 0.92 EPHX2 (0.61) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL7368975 0.86 RORC (0.56) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL15480407 0.86 HDAC1 (0.70) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL517697 0.85 HDAC3 (0.86) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL3238549 0.85 HDAC1 (0.65) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL5547454 0.85 HDAC1 (0.53) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL4096977 0.85 HDAC1 (0.55) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL7399320 0.85 HDAC3 (0.73) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL8180029 0.85 HDAC1 (0.55) HDAC1HDAC3HDAC2HDAC6HDAC10
SCHEMBL8132303 0.85 HDAC1 (0.55) HDAC1HDAC3HDAC2HDAC6HDAC10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENT AB (SE) 2017-01-26 US disclosed
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS CERENO SCIENTIFIC AB 2014-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140051716-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC3 1/4885HDAC2 3/4885
US-20170020874-A1 COMPOUNDS AND METHODS FOR IMPROVING IMPAIRED ENDOGENOUS FIBRINOLYSIS USING HISTONE DEACETYLASE INHIBITORS HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC3 1/4885HDAC2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.